不同剂量恩度联合顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床分析
|
摘要
目的:分析不同剂量恩度联合顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床效果。方法:采取收治的56例非小细胞肺癌恶性胸腔积液作为研究对象,随机分为研究组与对照组各28例。对照组给予30 mg恩度加常规剂量顺铂胸腔灌注治疗;研究组给予60 mg恩度加常规剂量顺铂胸腔灌注治疗。监测两组治疗前后的肺功能及血气分析、近期疗效。结果:经过治疗,两组患者第一秒用力呼气容积(FEV_1)、FEV_1/用力肺活量(FVC)、FEV_1占预计值的百分比(FEV_1%Pred)、氧分压(PaO_2)及二氧化碳分压(PaCO_2)均显著优于治疗前,差异有统计学意义(P<0.05);但研究组治疗后FEV_1、FEV_1%Pred、FEV_1/FVC、PaO_2、PaCO_2评分均显著优于对照组,差异有统计学意义(P<0.05);研究组近期疗效缓解率显著高于对照组,差异有统计学意义(P<0.05)。结论:对于非小细胞肺癌恶性胸腔积液患者,60 mg恩度联合顺铂胸腔灌注的临床效果更为理想,且安全性较为可靠。
Objective To analyze the clinical effect of different doses of rh-endostatin combined with cisplatin in the treatment of malignant pleural effusion in non-small cell lung cancer.Method 56 cases of malignant pleural effusion of non-small cell lung cancer treated in our hospital were selected as the research object and divided into study group and control group with random number grouping method,28 cases in each group.The control group was given 30 mg rh-endostatin plus routine dose of cisplatin thoracic perfusion,while the study group was given 60 mg rh-endostatin plus routine dose of cisplatin thoracic perfusion.The pulmonary function,blood gas analysis and short-term efficacy of the two groups were monitored before and after treatment.Results After treatment,FEV_1,FVC,FEV_1% Pred,PaO_2 and PaCO_2in the two groups were significantly better than those before treatment, the difference was statistically significant(P<0.05),but the scores of FEV,FEV_1% Pred,FEV_1/FVC,PaO_2 and PaCO_2 in the study group were significantly better than those in the control group, the difference was statistically significant(P<0.05);the short-term remission rate of the study group was significantly higher than that of the control group, the difference was statistically significant(P<0.05).Conclusion For patients with malignant pleural effusion of non-small cell lung cancer,60 mg rh-endostatin combined with cisplatin thoracic perfusion is more effective and safe.
Objective To analyze the clinical effect of different doses of rh-endostatin combined with cisplatin in the treatment of malignant pleural effusion in non-small cell lung cancer.Method 56 cases of malignant pleural effusion of non-small cell lung cancer treated in our hospital were selected as the research object and divided into study group and control group with random number grouping method,28 cases in each group.The control group was given 30 mg rh-endostatin plus routine dose of cisplatin thoracic perfusion,while the study group was given 60 mg rh-endostatin plus routine dose of cisplatin thoracic perfusion.The pulmonary function,blood gas analysis and short-term efficacy of the two groups were monitored before and after treatment.Results After treatment,FEV_1,FVC,FEV_1% Pred,PaO_2 and PaCO_2in the two groups were significantly better than those before treatment, the difference was statistically significant(P<0.05),but the scores of FEV,FEV_1% Pred,FEV_1/FVC,PaO_2 and PaCO_2 in the study group were significantly better than those in the control group, the difference was statistically significant(P<0.05);the short-term remission rate of the study group was significantly higher than that of the control group, the difference was statistically significant(P<0.05).Conclusion For patients with malignant pleural effusion of non-small cell lung cancer,60 mg rh-endostatin combined with cisplatin thoracic perfusion is more effective and safe.
引文
[1] 陆向东,张汀荣.重组人血管内皮抑制素联合顺铂胸腔内灌注治疗晚期非小细胞肺癌恶性胸腔积液的疗效[J].江苏医药,2017,43(14):1023.
[2] 闫晓洲,付晓东,赵子明.顺铂联合单孔胸腔镜胸膜固定术治疗恶性胸腔积液的临床研究[J].中国处方药,2018,16(12):83.
[3] 常春艳.顺铂治疗恶性胸腔积液临床疗效分析[J].中国实用医药,2018,13(23):105.
[4] 周燕群,郭勇,杨笑奇.恩度联合顺铂腔内注射治疗肺癌合并恶性胸腔积液meta分析[J].实用肿瘤杂志,2018,33(6):553.
[5] 赵子舒,杨雁鸿,王小玉,等.重组人血管内皮抑制素联合顺铂治疗非小细胞肺癌恶性胸腔积液的疗效及安全性的Meta分析[J].亚洲肿瘤科病例研究,2018,7(3):17.
[2] 闫晓洲,付晓东,赵子明.顺铂联合单孔胸腔镜胸膜固定术治疗恶性胸腔积液的临床研究[J].中国处方药,2018,16(12):83.
[3] 常春艳.顺铂治疗恶性胸腔积液临床疗效分析[J].中国实用医药,2018,13(23):105.
[4] 周燕群,郭勇,杨笑奇.恩度联合顺铂腔内注射治疗肺癌合并恶性胸腔积液meta分析[J].实用肿瘤杂志,2018,33(6):553.
[5] 赵子舒,杨雁鸿,王小玉,等.重组人血管内皮抑制素联合顺铂治疗非小细胞肺癌恶性胸腔积液的疗效及安全性的Meta分析[J].亚洲肿瘤科病例研究,2018,7(3):17.